Khiron Life Sciences Corp. (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC) has signed an exclusive agreement with Medlive, a leading marketer and distributor of pharmaceutical products to clinics, hospitals and pharmacies in southern Brazil.
The exclusive agreement will further Khiron’s position as a leading vertically integrated cannabis supplier in Latin America. The company will supply Medlive’s network of over 3,000 clinics and hospitals in southern Brazil. As part of the agreement physicians in Medlive’s extensive network will receive medical education and training related to Khiron products.
Medlive is a leader in the distribution of medical and hospital products in the south of Brazil, serving hospitals and clinics in the public and private sectors. The company has a wide portfolio of medicines, nutritional products, and solutions that are applied across the supply chain for conditions including cancer treatments and clinical nutrition, among others.
“Brazil represents one of the most important markets in Latin America, with its massive population and its acceptance of medical cannabis. Together with Medlive we are now positioned to begin educating health professionals and driving prescriptions for our medical cannabis products, and ultimately focus on our objective to help patients in Brazil who can benefit from medical cannabis,” comments Alvaro Torres, Khiron CEO and director. “Medlive is recognized as an important medical marketing organization in the region and we could not have a better partner to help us achieve these goals.”
Khiron is already the dominant integrated medical cannabis company in Latin America, in addition to its activities in North America and Europe, and is licensed in Colombia for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis.
On February 7th, 2020 the Company announced authorisation from the Brazilian Health Regulatory Agency (ANVISA) for Khiron medical cannabis product to be imported for use on an individual patient basis.
The medical cannabis market in Brazil is anticipated to grow to 3.4 million patients and a market of US$1.4 Billion within three years, including serving patients with chronic pain conditions (Source: New Frontier Data 2017). Further, total requests for medical cannabis have tripled since 2015 (Source: ANVISA) and today, approximately 1,100 physicians are now prescribing medical cannabis to their patients.
“With the rapid globalization of legalized medical cannabis, including here in Brazil, there is an important need to bring product education and information to the country’s health professionals. When medical professionals think of medical cannabis here, they think of Khiron. Khiron was the best choice to have as a partner, and to bring their highly regarded product research and development expertise to our health network,” comments Adriana Marques, Medlive Managing Director.
Source: Khiron Life Sciences Corp.